Chonluten
Also known as: Peptídeo respiratório
Molecular Identifiers
Overview
Respiratory system bioregulatory tripeptide developed by the Khavinson group. Regulates gene expression in respiratory epithelium and modulates pulmonary mucosal immune function. Used in short cycles for respiratory tract support.
The interest in Chonluten lies in trophic support to the respiratory epithelium: regulation of gene expression in the airways, modulation of pulmonary mucosal immunity, and support for epithelial barrier integrity. It has been proposed as an adjunct in chronic bronchitis, low-grade pulmonary inflammatory processes, and respiratory recovery.
It has no approval as a medicine by the FDA, EMA, or ANVISA. It circulates mainly through compounding pharmacies and specialized suppliers of Russian-school peptides, in short cycles of 10-20 days repeated 2-4 times per year, sometimes combined with Bronchogen in pulmonary bioregulation protocols.
It belongs to the family of short bioregulatory peptides developed by Vladimir Khavinson's group in St. Petersburg, which applied the same logic to several organs. The available evidence is concentrated in Russian-language literature and preclinical studies; robust international clinical trials are still limited.
Within the Khavinson family, Chonluten is most often compared to Bronchogen, also targeted at the respiratory system: Chonluten (the Glu-Asp-Gly tripeptide) is described with a stronger focus on pulmonary mucosal immunity and epithelial barrier, while Bronchogen (the Ala-Glu-Asp-Leu tetrapeptide) is presented as acting more on the bronchial mucosa. All of this comparative literature is largely Russian and preclinical.
EDG Glu-Asp-Gly Half-life
~2-4 hours
Administration Route
Subcutaneous or intramuscular
Category
Specialized Research
Mechanism of Action
- Regulation of gene expression in respiratory epithelium
- Modulation of pulmonary mucosal immune function
- Support for airway epithelial barrier integrity
- Normalization of pulmonary surfactant production
- Bioregulatory effect on respiratory organs
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 1-2 capsules orally (0.2 g per capsule, containing bronchial tissue peptide complex) |
| Frequency | 1-2 times daily, with meals |
| Timing | With meals |
| Duration | 10-30 days per cycle, repeat the course every 4-6 months |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Injection site pain
- Local redness (rare)
Product Properties
| Purity | >95% |
| Appearance | White lyophilized powder |
| Solubility | Soluble in water and bacteriostatic water |
| Source | Solid-phase peptide synthesis (SPPS) |
| Storage | Lyophilized: -20°C for up to 2 years, 2-8°C for up to 6 months. Reconstituted: 2-8°C for up to 4 weeks. Protect from light and moisture. Avoid repeated freeze-thaw cycles. |
Presentations & Preparation
Vials of Chonluten found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: 2 ml per vial
- Slowly inject the diluent against the vial wall
- Gently swirl until fully dissolved
- Never shake
Storage
- Lyophilized: Refrigerated 2-8°C
- Reconstituted: Refrigerated 2-8°C (up to 30 days)
- Protect from direct light
- Do not freeze after reconstitution
Scientific Studies
Published studies on Chonluten.
Related Peptides
Aviptadil
50-150 mcg per administration (IV or subcutaneous) · 1-3 times daily per protocol
B7-33
Bronchogen
1-2 capsules orally (0.2 g per capsule, containing AKS-B peptide complex) · 1-2 times daily, with meals
Cardiogen
Crystagen
1-2 capsules orally (0.2 g per capsule, containing AKS-6 peptide complex) · 1-2 times daily, before meals
Dalargin
1-2 mg per injection (subcutaneous or intramuscular) · 1-2 times daily